<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ruchi</forename><surname>Baghel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandeep</forename><surname>Grover</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Paediatrics</orgName>
								<orgName type="department" key="dep2">Division of Pneumonology-Immunology</orgName>
								<orgName type="institution">Charit e University Medical Centre</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Harpreet</forename><surname>Kaur</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ajay</forename><surname>Jajodia</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chitra</forename><surname>Rawat</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ankit</forename><surname>Srivastava</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Suman</forename><surname>Kushwaha</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Institute of Human Behavior &amp; Allied Sciences (IHBAS)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rachna</forename><surname>Agarwal</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Institute of Human Behavior &amp; Allied Sciences (IHBAS)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sangeeta</forename><surname>Sharma</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Institute of Human Behavior &amp; Allied Sciences (IHBAS)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ritushree</forename><surname>Kukreti</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Genomics and Integrative Biology (IGIB)</orgName>
								<orgName type="institution">Council of Scientific and Industrial Research (CSIR)</orgName>
								<address>
									<settlement>Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Molecular</forename><surname>Medicine</surname></persName>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">IGIB (CSIR)</orgName>
								<address>
									<addrLine>Mall Road</addrLine>
									<postCode>110 007</postCode>
									<settlement>Unit, Delhi</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">8E7BA7D3DA431F658138525B9C98EDA6</idno>
					<idno type="DOI">10.1111/cns.12570</idno>
					<note type="submission">Received 22 June 2015; revision 25 April 2016; accepted 26 April 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:49+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Epilepsy response</term>
					<term>GABRA1</term>
					<term>Monotherapy</term>
					<term>Phenytoin</term>
					<term>SCN1A</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Aim: The present study aimed to evaluate association of genetic variants on drug response and therapy optimization parameters in patients treated with first-line antiepileptic drugs (AEDs).</s><s>Genetic variants from ion channels, their functionally related genes, and synaptic vesicle cycle (SVC) genes with a potential role in epilepsy pathophysiology were thus prioritized.</s><s>Methods: A total of 12 genes from ion channels and related gene set and seven genes from SVC comprising 155 SNPs were genotyped and evaluated with drug response, dose levels, and drug levels in 408 patients with epilepsy.</s><s>Results: Both GABRA1 and SCN1A variants showed haplotypic and diplotypic associations in response to phenytoin (PHT).</s><s>Diplotype analysis of GABRA1 variants revealed association of rs12658835|rs7735530 (AG/AG) (P-value corrected = 0.034, OR = 3.75, 95% CI = 1.36-11.05)</s><s>and rs12658835| rs7735530|rs7732641|rs2279020 (AGCA/AGCA) (P-value corrected = 0.035, OR = 2.48, 95% CI = 0.96-6.41)</s><s>with recurrent seizures.</s><s>SCN1A haplotype rs6432860|rs3812718 (AC: P-value corrected = 0.022, OR = 2.72, 95% CI = 1.39-5.35)</s><s>and diplotype (AC/AC: P-value corrected = 0.034, OR = 6.42, 95% CI = 1.10-65.76)</s><s>were further observed to be associated with recurrent seizures.</s><s>With respect to therapy optimization parameters, we observed significantly lower dose-adjusted drug levels at maximum dose of PHT in patients carrying AC/AC diplotype (P-value = 0.021).</s><s>Conclusion: The results further substantiate the role of GABRA1 in PHT mode of action and contribution of SCN1A in response and therapy optimization with PHT monotherapy.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Epilepsy is a complex neurological disorder characterized by recurrent and unprovoked seizures.</s><s>It affects nearly 50 million people worldwide with a prevalence of 5.3/1000 person in India <ref type="bibr" target="#b0">[1]</ref>.</s><s>A variety of antiepileptic drugs (AEDs) are available in the market with newer drugs also developing constantly.</s><s>However, first-generation AEDs mainly carbamazepine (CBZ), phenytoin (PHT), valproate (VP), and phenobarbitone (PB) still remain as the major prescriptions <ref type="bibr" target="#b1">[2]</ref>.</s><s>Despite availability of appropriate therapy, patient response is highly variable with 30% failing to respond to treatment <ref type="bibr" target="#b2">[3]</ref>.</s><s>Mechanism of action of first-generation AEDs is considered to be well known with their possible metabolizing enzymes, transporters, and targets well characterized and well explored in pharmacogenetic studies conducted for understanding the variable patient response.</s><s><ref type="bibr" target="#b3">[4]</ref>.</s><s>The results have been inconclusive and conflicting with no recommendations available to date for prediction of antiepileptic dose, drug level, and drug response on the basis of genetic markers.</s><s>Therefore, due to unavailability of clinically applicable results, disparities overshadow patient response, with no uniformity among individuals in terms of dosing and response <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b9">[9]</ref>.</s></p><p><s>This hints toward the need for further exploration of mechanisms of action of AEDs.</s><s>Majorly, ion channels and receptors such as sodium channels, calcium channels, GABA and glutamate receptors, GABA transporters, and GABA aldehyde dehydrogenase are known to be the targets of AEDs.</s><s>Both CBZ and PHT are known to target voltage-dependent sodium channels, whereas VP and PB are known to target GABAergic neurotransmitter system <ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref>.</s><s>Additionally, potentiation of GABAergic neurotransmission has also been reported with CBZ and PHT <ref type="bibr" target="#b13">[13]</ref>.</s><s>In addition, there may be many other potential molecules in nervous system.</s><s>For instance SV2A, a nonion channel molecule belonging to presynaptic region of neurons is a possible target of levetiracetam <ref type="bibr" target="#b14">[14]</ref>.</s><s>Of the presynaptic gene assembly, genes such as synapsin, syntaxin, and syndapin have been well explored for their role in epilepsy genetics in humans.</s><s>On the other hand, genes such as dynamin 1 and SNAP-25 have only been explored for genetics in mouse models.</s><s>However, the understanding of presynaptic gene involvement in AEDs mode of action is still in its infancy <ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>. Therefore, gene prioritization for pharmacogenetic studies may thus be reviewed and may also include evaluation of epilepsy pathophysiology genes other than classic ion channel genes <ref type="bibr" target="#b11">[11,</ref><ref type="bibr" target="#b18">19]</ref>.</s></p><p><s>Therefore, to understand the interpatient variability, genetic variants from ion channels and their functionally related genes (mainly sodium channels, GABA and glutamate receptors, GABA transporter, and GABA aldehyde dehydrogenase) along with the presynaptic (synaptic vesicle cycle [SVC]) genes with potential involvement in disease pathophysiology were evaluated for their influence on variable AED response and therapy optimization parameters, that is, dose and dose-adjusted drug levels of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects</head><p><s>A total of 478 epilepsy patients of North Indian ethnicity were enrolled from the Outpatient Department of Neurology at the Institute of Human Behaviour and Allied Sciences (Delhi, India).</s><s>Prior to patient enrollment, the study protocol was approved by institutional ethics committee.</s><s>All the enrolled patients fulfilled the inclusion and exclusion criteria of the study.</s><s>Inclusion criteria were as follows: patients above five years of age with at least two unprovoked seizures, on treatment with any of the four first-line AEDs, that is, PHT, CBZ, VP, PB, or their combinations/multitherapy (MT).</s><s>Exclusion criteria were as follows: patients with gross neurological deficits such as mental retardation, motor deficits, and imaging abnormalities including tumor, multiple neurocysticercosis, tuberculoma, vascular malformation and atrophic lesions, patients who had severe hepatic and renal disorders, and pregnant women <ref type="bibr" target="#b19">[20]</ref>.</s><s>Diagnosis and treatment were performed by an experienced neurologist.</s><s>For seizure types, seizure diagnosis, and their classification, guidelines of International League Against Epilepsy (ILAE) 1981 and 1989 were followed <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>A detailed questionnaire of the project which included gender, age at seizure onset, type of seizure, baseline seizure frequency, AED prescription, neurological examination, brain imaging was used for data collection.</s><s>Other baseline evaluations of the patients included all routine investigations such as biochemistry profile, hematology profile, serum drug-level estimation, and DNA extraction.</s><s>Blood samples were collected from all the patients after obtaining written consent forms in accordance with the institutional ethics committee approval.</s><s>Patients were followed up at 2nd, 4th, 8th, and 12th months from the date of enrollment and were evaluated for seizure control, compliance to medications, side effects, and therapeutic drug monitoring (TDM).</s><s>At the end of one-year study duration, all patients were assessed for seizure control based on the number of seizures experienced during the follow-up duration which did not include the initial 2-month period during which all patients were assumed to attain the steady-state drug levels.</s><s>Patients who remained seizure free in the last 10 months, despite appropriate AED treatment, were kept in "no-seizure" group, whereas those with one or more seizures during the same period were kept in "recurrent seizure" group.</s><s>Out of the enrolled 478 patients, a total of 408 patients completed the study duration (Table <ref type="table" target="#tab_0">1</ref>).</s><s>An additional cohort of 170 ethnicity matched unrelated healthy individuals were also enrolled for the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genes and SNP Prioritization</head><p><s>Genomic DNA was extracted from peripheral blood cells by utilizing a modified version of salting out method <ref type="bibr" target="#b22">[23]</ref>.</s><s>A total of 12 ion channels, their functionally related genes, and seven SVC genes comprising 210 SNPs were prioritized (Tables <ref type="table" target="#tab_4">S1 and S2</ref>).</s><s>The genes prioritized for the present study thus comprised ion channels and their functionally related genes: sodium channel genes encoding a subunit type 1 (SCN1A), a subunit type 2 (SCN2A), and b subunit type 1 (SCN1B), GABA and glutamate receptors including GABRA1, GABRA6, GABRB3, GABRG2, GRIK1 and GRIN1, GABA transporter (SLC6A11), and GABA aldehyde dehydrogenase (ALDH5A1).</s><s>Among the presynaptic genes (SVC genes), a comprehensive gene list of SNAP25, STX1A, STXBP1, SYN2, SYT1, VAMP2, EFHC1 was prioritized.</s><s>SNPs were prioritized on the basis of literature reports stating their genetic association <ref type="bibr" target="#b14">[14,</ref><ref type="bibr" target="#b15">15]</ref> and probable functional significance depending on the gene location and prediction softwares (SNP function prediction, FuncPred which gives integrative results for PolyPhen, SNP3D, miRNA binding, etc.) <ref type="bibr" target="#b23">[24]</ref>.</s><s>With the aim of covering the entire gene, SNPs from noncoding sequences, that is, intron and other 3 0 and 5 0 UTRs, as well as coding region, that is, synonymous and nonsynonymous SNPs, were prioritized.</s><s>Additionally, SNPs from 5 0 and 3 0 upstream region of the gene were also prioritized.</s><s>A total of 186 SNPs which passed the assay designing and initial optimization of reactions were finally genotyped by iPLEX Gold, Sequenom MassARRAY Genetic Analysis System (Sequenom, Inc., San Diego, CA, USA) using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.</s><s>To determine precision, a random 5% of the samples were later regenotyped by sequencing using the BigDye Terminator kit (version 3.1; Applied Biosystems, Foster City, CA, USA).</s><s>Further to rule out the issue of population stratification, nine randomly chosen autosomal microsatellite markers not linked to epilepsy (D10S548, D10S196, D10S1653, D11S937, D11S901, D13S218, D13S175, D20S115, and D20S107) were also genotyped in all the samples.</s><s>The results were then analyzed on GeneScan module of the Genotyper software, version 3.7 (Applied Biosystems).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitation of AEDs in Serum Samples</head><p><s>Total serum drug concentration of PHT, CBZ, VPA, and PB were measured by Auto-analyzer from Logitech Pvt. Ltd. (Model Echo) using cloned enzyme donor immunoassay (CEDIA â ) II Assay kits by Microgenics Corporation, USA.</s><s>All measurements and interpretations were performed in the neuropsychopharmacology department of IHBAS under the supervision of an experienced clinical pharmacologist.</s><s>The inter-run assay precision for AEDs studied was &lt;10% for follow-ups and evaluation.</s><s>Due to the variability in oral doses among patients, dose-adjusted serum concentrations were calculated for each patient by dividing the steady-state concentration (mg/L) by the daily dose (mg/day).</s><s>The "maintenance dose" of a given drug was defined as the dose, which remained unchanged for successive visits in the 12-month period.</s><s>On the other hand "maximum dose" was defined as the maximum dose prescribed to the patients during the follow-up time period.</s><s>To obtain the average steady-state serum drug levels at maintenance dose, mean of drug-level measurements over a period when consecutive doses were documented was used.</s><s>Similarly, average serum levels at maximum dose corresponded to drug levels over the period when consecutive maximum documented dose was used.</s><s>All the significantly associated SNPs were then observed for linkage disequilibrium (LD) based on healthy controls of same ethnicity using tagger algorithm of Haploview 4.2 <ref type="bibr" target="#b25">[26]</ref>.</s><s>SNPs showing high LD (r 2 &gt;0.9) were dropped from further analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Remaining significantly associated SNPs were further subjected to haplotype identification by means of sliding window approach of PLINK <ref type="bibr" target="#b24">[25]</ref>.</s><s>Prior to haplotype construction, PHASE (Ver.</s><s>2.1) software based on the Bayesian algorithm was used for phasing the entire genotype data with parameter value of 100 iterations a thinning interval of 10, and a burn-in value of 100 in the Markov chain Monte Carlo simulations was used <ref type="bibr" target="#b26">[27]</ref>.</s><s>This was followed by diplotype analysis of the significantly associated haplotypes.</s><s>Significantly associated diplotypes were than evaluated for association with therapy optimization parameters.</s><s>To test for population stratification, the genotype frequencies of unlinked markers in cases and controls were compared using Pearson's chi-square test utilizing STRAT software <ref type="bibr" target="#b27">[28]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Of the 408 patients who completed the one-year study duration, 379 (92.65%) were on monotherapy (24  <ref type="table" target="#tab_0">1</ref>).</s><s>The test for population stratification using all of the nine unlinked markers was not significant in our study suggesting ethnically homogeneous population (v 2 = 76.67,</s><s>df = 60, P-value = 0.072).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of Genetic Variants</head><p><s>Association analysis with drug response was first performed in a pooled cohort of all patients on different drug therapies.</s></p><p><s>Later stratified analysis was conducted in each drug therapy group for association with drug response, dose levels, and drug levels.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>All Drugs</head><p><s>Pooled analysis of all drug groups revealed significant associations for a total of 15 SNPs spanning five genes, but none of them could remain significant after accounting corrections for multiple comparisons (Table <ref type="table" target="#tab_4">S2</ref>).</s><s>Further, haplotype analysis was performed on SNPs with significant uncorrected P-values.</s><s>However, none of the haplotype could remain significant postcorrection for multiple comparisons.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phenytoin (PHT)</head><p><s>Upon stratification for PHT treatment, we observed significant association of 13 SNPs from three genes including SCN1A (rs2298771, rs6432860, rs3812718), GABRA6 (rs3811995, rs13184586, rs3219151), and GABRA1 (rs12658835, rs7735530, rs7732641, rs1157122, rs2279020, rs2290732, rs998754), but none could remain significant postcorrection for multiple comparisons (Table <ref type="table" target="#tab_5">S3</ref>).</s><s>Among all the variants, rs1157122 of GABRA1 had the most significant uncorrected P-value of 8.28 9 10 À4 .</s><s>Further evaluation of LD information on SNPs showing significant but uncorrected association in healthy control population revealed tight LD among following associated SNPs: rs6432860 and rs2298771 of SCN1A (r 2 = 0.92), rs3219151 with rs3811995 (r 2 = 0.906) and rs13184586 (r 2 = 0.929) of GABRA6, rs7732641 with rs1157122 of GABRA1 (r 2 = 0.98), and rs2290732 with rs998754 (r 2 = 0.99) of GABRA.</s><s>Exclusion of tagged SNPs from every gene was followed by haplotype analysis of the remaining five SNPs from GABRA1 (rs12658835, rs7735530, rs7732641, rs2279020, and rs2290732) and two SNPs (rs6432860 and rs3812718) from SCN1A.</s><s>GABRA1 showed several significantly associated haplotypes ranging from two-to five-marker combinations and SCN1A also showed a significant two-marker haplotype.</s></p><p><s>Of the several significantly associated haplotypes, the longest fivemarker haplotype for GABRA1 was rs12658835|rs7735530| rs7732641|rs2279020|rs2290732 (AATGA: P corrected value = 0.022, OR = 0.30, 95% CI = 0.12-0.77)</s><s>and (AGCAG:  <ref type="table" target="#tab_4">2A</ref>).</s><s>Furthermore, SCN1A also showed significant overrepresentation of rs6432860|rs3812718 (AC/AC: P corrected value = 0.0349, OR = 6.42, 95% CI = 1.10-65.76) in patients with "recurrent seizures" (Table <ref type="table" target="#tab_4">2B</ref>).</s><s>Analysis of therapy optimization parameters failed to reveal association of GABRA1 variants with dose and drug levels (Table <ref type="table" target="#tab_14">S4</ref>).</s><s>However, significantly higher levels of "dose-adjusted serum drug levels" at maximum dose were observed in patients carrying GG genotype of rs6432860 of SCN1A (P-value = 0.042).</s><s>This is in contrast to significantly lower "dose-adjusted drug levels" at maximum dose of PHT in patients harboring SCN1A AC/ AC diplotype (P-value = 0.021) (Table <ref type="table" target="#tab_5">3</ref>).</s></p><formula xml:id="formula_0">P corrected value = 0.022, OR = 2.</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Carbamazepine (CBZ)</head><p><s>With respect to CBZ treatment, a total of nine SNPs from six genes namely SCN2A (rs1007722), GABRA6 (rs13184586, rs3219151), GABRA1 (rs7732641), GABRG2 (rs209353), STX1A (rs6956879,  <ref type="table" target="#tab_4">S2</ref>).</s><s>Further LD determination in healthy control population revealed strong LD between rs3219151 and rs13184586 (r 2 = 0.93) of GABRA6.</s><s>As a result, only three genetic variants from STX1A could be carried forward for further haplotype analysis.</s><s>A 2-3 marker sliding window approach identified a borderline association of two-marker haplotype rs867500|rs4363087 (GT: P corrected value = 0.050, OR = 1.97, 95% CI = 1.24-3.13)</s><s>with a higher frequency (54.93%) in patients with "recurrent seizures" compared to patients with "no seizure" (39.38%) (Table <ref type="table" target="#tab_4">2A</ref>).</s><s>However, diplotype combination of haplotypic variants could not reveal significant association which limited any further analysis with CBZ dose and drug levels.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Valproate (VP)</head><p><s>In case of valproate monotherapy, we observed significant association of six SNPs from four genes CACNA1E (rs4652678, rs199930), SCN1A (rs1813502, rs3812718), GABRB3 (rs878960), and GRIK1 (rs466476), but none could withstand correction for multiple comparisons (Table <ref type="table" target="#tab_4">S2</ref>).</s><s>Further, LD information on variants from CACNA1E and SCN1A in healthy controls did not reveal any significant linkage.</s><s>However, none of the haplotypes from both genes showed any significant association.</s><s>The absence of any haplotype association refrained from conducting further association analysis of diplotypes and their influence on dose and drug levels.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phenobarbitone (PB)</head><p><s>With respect to association analysis in patients on PB treatment, a total of eight SNPs from four genes namely GABRG2 (rs209353), ALDH5A1 (rs2247845, rs1054899), SCN1B (rs67777826, rs5839 2252, rs2278995, rs2278996), and GRIK1 (rs2832495) revealed significant P-values which could not remain significant postcorrection for multiple comparisons (Table <ref type="table" target="#tab_4">S2</ref>).</s><s>The LD determination in healthy control population did not reveal any significant linkage.</s><s>Lastly, haplotype analysis did not yield any significant association which limited any further analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The identification of a genetic marker as a predictor for treatment response has been a long felt need in epilepsy therapeutics.</s><s>We hypothesized that genetic variants from ion channels and functionally related genes and genes from synaptic vesicle cycle (SVC) may affect response to first-line AEDs.</s><s>We conducted a comprehensive association study of 155 SNPs across 12 such genes (Table <ref type="table">S5</ref>).</s><s>Although single-marker analysis of all the genetic markers with drug response provided significant association signals across several loci, none could withstand correction for multiple comparisons.</s><s>Single SNP may not be the actual causal variant rather more than one SNP might be responsible.</s><s>SNPs do not transmit independently; rather, there is an intrinsic dependency of SNPs due to their combination as linked units into haplotypes and diplotypes.</s><s>Haplotypes and diplotypes are in fact more informative and have higher statistical power.</s><s>Therefore, in addition to single SNP association analysis, a multimarker/haplotype approach was adopted to increase the power of the study, thus providing a more holistic view of association <ref type="bibr" target="#b28">[29]</ref>.</s><s>The multimarker approach further led us to identification of significant associations of SCN1A and GABRA1 haplotypes and diplotypes in response to PHT monotherapy in patients with epilepsy.</s><s>GABA is well known to be a principal inhibitory neurotransmitter and alteration in expression or activity of genes encoding these receptors (GABAergic) is believed to be one of the main causes behind seizure pathophysiology which could further lead to altered drug response.</s><s>In the present study, majority of the GABRA1 variant haplotypes and diplotypes were observed to be overrepresented in patients with recurrent seizures.</s><s>The GABRA1 haplotypes comprised of SNPs spanning from 5 0 UTR (rs12658835) to 3 0 UTR (rs2290732) of the gene and included several intronic SNPs (rs7735530-intron 3, rs7732641-intron 6, rs2279020-intron 8) as well.</s><s>Although the longest associated fourmarker diplotype rs12658835|rs7735530|rs7732641|rs2279020 did not have 3 0 UTR SNP, the varied gene locations of SNPs reflected the gene coverage of the associated region.</s><s>This further highlighted the presence of long regions of high linkage within the gene and led us to identification of causal variants in our population.</s><s>Based on the functional prediction of the associated SNPs, we observed that 5 0 UTR SNP rs12658835 is present on the transcription factor binding site which may ultimately lead to impaired transcription of the GABRA1.</s><s>Further, it was also observed that the 3 0 UTR SNP rs2290732 is present on a miRNA binding site which may ultimately influence the GABRA1 gene regulation.</s><s>In conclusion, our data highlight the potential influence of GABRA1 gene as a whole on the development of recurrent seizure phenotype in epilepsy patients despite being on adequate treatment.</s></p><p><s>A recent report by Zhou et al. highlighted the importance of 3 0 UTR region of GABRA1 on CBZ tolerance <ref type="bibr" target="#b29">[30]</ref>.</s><s>It was observed that carriers of 3 0 UTR SNP rs2290732 GG genotype were less tolerant to CBZ therapy.</s><s>This may be attributed to poor seizure control or development of adverse drug reactions (ADRs).</s><s>Significant association of another GABRA1 variant rs2279020 with drug resistance was earlier observed in patients treated with CBZ, PHT, or VPA <ref type="bibr" target="#b30">[31]</ref>.</s><s>In light of evidence supporting the possible binding of both PHT and CBZ on GABA A receptor, CBZ associations may provide directions for genetic marker search for PHT response.</s><s>Similar to results reported by Zhou et al., our study also showed higher frequency of G allele of rs2290732 as a part of associated haplotypes (rs2279020_rs2290732:AG = 74.65%,</s><s>rs7732641_rs2279 020_rs2290732: CAG = 74.27%,</s><s>rs7735530_rs7732641_rs22790 20_rs2290732: GCAG = 74.29%,</s><s>rs12658835_rs7735530_rs773 2641_rs2279020_rs2290732: AGCAG = 74.28%)</s><s>and diplotypes (rs2279020_rs2290732:AG/AG = 51.35%) in recurrent seizure patients (Table <ref type="table" target="#tab_4">2A</ref>) <ref type="bibr" target="#b29">[30]</ref>.</s><s>An earlier report by Kumari et al. showed significant association of another SNP rs2279020 with drug resistance in ethnically similar North Indian epilepsy patients <ref type="bibr" target="#b31">[32]</ref>.</s><s>In the same year, Kim et al. reported the significant association of a gene-gene interaction model of four SNPs from GABRA1, EAAT3, and GAT3 including 5 0 UTR SNP rs12658835 from GABRA1 with epilepsy drug resistance <ref type="bibr" target="#b32">[33]</ref>.</s><s>Similarly, in our study, A allele of rs12658835 was observed to have higher frequency in diplotypic combination with other GABRA1 variants in patients showing "recurrent seizures."</s><s>In addition, SCN1A SNPs were also observed to be associated in response to PHT in our study.</s><s>A two-    marker haplotypic and diplotypic combination (rs6432860_ rs3812718, AC) of exonic SNP (rs6432860) and intronic splice variant (rs3812718) was observed to be significantly higher in patients with "recurrent seizures."</s><s>Of the associated haplotypes, rs6432860 is a synonymous SNP and was in LD with another significantly associated SNP rs2298771 (Ala1067Thr) which may alter structure and function of SCN1A.</s><s>The intronic SNP rs3812718 (IVS5-91G&gt;A) is known to be a functional variant and disrupts the consensus 5 0 splice donor site a highly conserved alternative exon (5N) resulting in altered proportion of neonate and adult exon 5 transcripts in adult brain tissue.</s><s>The study by Tate el al. was the first to describe the significant association of IVS5-91G&gt;A with maximum dose and drug concentration at maintenance dose of PHT as well as CBZ <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b35">35]</ref>.</s><s>However, another study of CBZ dosage in Austrian population failed to reveal the significant association <ref type="bibr" target="#b37">[36]</ref>.</s><s>Additionally, other studies also failed to replicate the associations <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b38">37]</ref>.</s><s>Later the IVS5-91AA genotype was also reported to be associated with CBZ-resistant epilepsy without any underlying influence on dose <ref type="bibr" target="#b39">[38]</ref>.</s><s>On the contrary, a recent study on Chinese patients revealed significant association of AA genotype with higher dose-adjusted CBZ concentration; however, it did not influence CBZ-resistant phenotype <ref type="bibr" target="#b40">[39]</ref>.</s><s>Another report by Zhou et al. observed that patients with AA genotype had higher maintenance dose and serum levels as compared to GG genotype carriers.</s><s>Additionally, this study also revealed significant association of GG genotype with higher retention rates of CBZ.</s><s>The report has also showed significant association of the variant with CBZ tolerability.</s><s>Although our study did not find significant association of IVS5-91G&gt;A with therapy optimization parameters, we did observe significant association of another variant rs6432860 from the same gene with drug levels.</s><s>It was observed that genotypic distribution of rs6432860 had significant influence on dose-adjusted drug levels at maximum PHT dose in the order AA&lt;GA&lt;GG (P = 0.042).</s><s>And lastly, both the SNPs (rs6432860 and IVS5-91G&gt;A) were observed to be significantly associated with therapy optimization parameters (dose and drug levels), when present in diplotypic combination.</s><s>We observed a significant association of SCN1A diplotype rs6432860|rs3812718 (AC) with lower dose-adjusted drug levels at maximum PHT dose (P-value = 0.021).</s><s>Being a drug target, significant association of SCN1A may not affect the metabolism of drug directly rather it may alter the structure or function of the ion channel.</s><s>The altered sensitivity could further lead to a change in the dose requirement for efficacious treatment which may then indirectly result in the altered serum drug levels <ref type="bibr" target="#b33">[34]</ref>.</s><s>In fact, association of drug levels with drug targets is considered to be more informative and stronger as compared to dose, because drug levels rule out the possibility of underlying pharmacokinetic variability.</s><s>A comprehensive list of all pharmacogenetic studies exploring GABRA1 and SCN1A along with their findings in different worldwide populations has been further summarized in Table 4 <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b35">[35]</ref><ref type="bibr" target="#b37">[36]</ref><ref type="bibr" target="#b39">[38]</ref><ref type="bibr" target="#b40">[39]</ref><ref type="bibr" target="#b41">[40]</ref><ref type="bibr" target="#b42">[41]</ref><ref type="bibr" target="#b43">[42]</ref><ref type="bibr" target="#b45">[43]</ref><ref type="bibr" target="#b46">[44]</ref><ref type="bibr" target="#b47">[45]</ref><ref type="bibr" target="#b48">[46]</ref><ref type="bibr" target="#b49">[47]</ref><ref type="bibr" target="#b50">[48]</ref><ref type="bibr" target="#b51">[49]</ref><ref type="bibr" target="#b52">[50]</ref><ref type="bibr" target="#b53">[51]</ref><ref type="bibr" target="#b54">[52]</ref><ref type="bibr" target="#b55">[53]</ref><ref type="bibr" target="#b56">[54]</ref><ref type="bibr" target="#b57">[55]</ref><ref type="bibr" target="#b58">[56]</ref>.</s></p><p><s>In summary, present study reports significant overrepresentation of GABRA1 and SCN1A variants in patients with "recurrent seizures" who were on PHT monotherapy.</s><s>Association of GABRA1 variants further supports mode of action of PHT through a1 subunit of GABRA1.</s><s>Detailed functional analysis of GABRA1 genetic architecture is required to highlight the exact mechanism by which GABRA1 influences drug response.</s><s>In silico analysis supported by functional experiments may also further highlight the possible binding sites and affinity of PHT for GABRA1 receptor.</s><s>Furthermore, association of SCN1A variants also highlights its role in poor response to PHT monotherapy, possibly by modulating serum drug levels.</s><s>Although we did observe several significant associations supported by functional relevance, our study has its own limitations.</s><s>In an attempt to achieve a homogenous patient pool in terms of phenotype and drug therapy, we adopted a stringent inclusion and exclusion criteria.</s><s>We further excluded all heterogeneous complex phenotypes and multitherapy patients from the final analysis.</s><s>This has resulted in small patient size which is the major limitation of the present study.</s><s>Hence, some of the modest associations reported (P-values &gt;0.01) in the present study may turn out to be false positive.</s><s>On the other hand, we did observe several strong and well-powered associations.</s><s>Despite being significant, results of the present may be viewed cautiously and replication of these associations needs to be demonstrated in larger cohorts of similar and different ethnicities.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Demographic characteristics of 408 epilepsy patients</s></p></div></figDesc><table><row><cell>Total</cell><cell>(n = 408 [100%])</cell><cell></cell><cell>22.2 AE 9.54, (406)</cell><cell></cell><cell>48.2 AE 13.0, (399)</cell><cell></cell><cell>36 (8.93)</cell><cell>195 (48.4)</cell><cell>121 (30.0)</cell><cell>51 (12.7)</cell><cell></cell><cell>238 (58.3)</cell><cell>170 (41.7)</cell><cell></cell><cell>247 (60.5)</cell><cell>9 (2.21)</cell><cell>76 (18.6)</cell><cell></cell><cell>15 (3.68)</cell><cell>33 (8.09)</cell><cell></cell><cell>26 (6.37)</cell><cell></cell><cell>232 (56.9)</cell><cell>176 (43.1)</cell><cell></cell><cell>10 (1.00-42.8), 328</cell><cell></cell><cell>12.05 (2.30-141), 256</cell><cell></cell><cell>1.74 (0.20-21.7), 254</cell><cell></cell></row><row><cell>Multitherapy (MT)</cell><cell>(n = 29 [7.11%])</cell><cell></cell><cell>22.3 AE 10.3, (29)</cell><cell></cell><cell>51.5 AE 19.9, (28)</cell><cell></cell><cell>5 (17.2)</cell><cell>16 (55.2)</cell><cell>5 (17.2)</cell><cell>3 (10.3)</cell><cell></cell><cell>24 (82.8)</cell><cell>5 (17.2)</cell><cell></cell><cell>15 (51.7)</cell><cell>2 (6.90)</cell><cell>7 (24.1)</cell><cell></cell><cell>1 (3.45)</cell><cell>4 (13.8)</cell><cell></cell><cell>0 (0.00)</cell><cell></cell><cell>7 (24.1)</cell><cell>22 (75.9)</cell><cell></cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell></row><row><cell>Phenobarbitone (PB)</cell><cell>(n = 32 [7.84%])</cell><cell></cell><cell>26.7 AE 12.7, (32)</cell><cell></cell><cell>51.0 AE 8.97, (32)</cell><cell></cell><cell>2 (6.25)</cell><cell>17 (53.1)</cell><cell>7 (21.9)</cell><cell>6 (18.7)</cell><cell></cell><cell>19 (59.4)</cell><cell>13 (40.6)</cell><cell></cell><cell>25 (78.1)</cell><cell>0 (0.00)</cell><cell>4 (12.5)</cell><cell></cell><cell>0 (0.00)</cell><cell>1 (3.13)</cell><cell></cell><cell>2 (6.25)</cell><cell></cell><cell>21 (65.6)</cell><cell>11 (34.4)</cell><cell></cell><cell>1.87 (1.00-4.70), 29</cell><cell></cell><cell>22.51 (2.30-48.8), 22</cell><cell></cell><cell>11.7 (1.40-21.7), 22</cell><cell></cell></row><row><cell>Valproate (VP)</cell><cell>(n = 85 [20.83%])</cell><cell></cell><cell>20.1 AE 8.10, (85)</cell><cell></cell><cell>49.0 AE 13.8, (82)</cell><cell></cell><cell>3 (3.61)</cell><cell>46 (55.4)</cell><cell>26 (31.3)</cell><cell>8 (9.64)</cell><cell></cell><cell>63 (74.1)</cell><cell>22 (25.9)</cell><cell></cell><cell>48 (56.5)</cell><cell>2 (2.35)</cell><cell>6 (7.06)</cell><cell></cell><cell>3 (3.53)</cell><cell>6 (7.06)</cell><cell></cell><cell>20 (23.5)</cell><cell></cell><cell>50 (58.8)</cell><cell>35 (41.2)</cell><cell></cell><cell>15 (6.70-42.8), 75</cell><cell></cell><cell>84 (6-141), 55</cell><cell></cell><cell>5.72 (0.20-12.8), 55</cell><cell></cell></row><row><cell>Carbamazepine (CBZ)</cell><cell>(n = 168 [41.18%])</cell><cell></cell><cell>21.4 AE 8.60, (166)</cell><cell></cell><cell>47.1 AE 11.9, (166)</cell><cell></cell><cell>15 (8.98)</cell><cell>82 (49.1)</cell><cell>51 (30.5)</cell><cell>19 (11.4)</cell><cell></cell><cell>55 (32.7)</cell><cell>113 (67.3)</cell><cell></cell><cell>91 (54.2)</cell><cell>3 (1.79)</cell><cell>41 (24.4)</cell><cell></cell><cell>11 (6.55)</cell><cell>17 (10.1)</cell><cell></cell><cell>3 (1.79)</cell><cell></cell><cell>97 (57.7)</cell><cell>71 (42.3)</cell><cell></cell><cell>10.9 (2.70-26.7), 146</cell><cell></cell><cell>9.4 (3.1-117.8), 115</cell><cell></cell><cell>0.86 (0.30-9.80), 115</cell><cell></cell></row><row><cell>Phenytoin (PHT)</cell><cell>Phenotypic characteristics (n = 94 [23.04%])</cell><cell>Age (years)</cell><cell>Mean AE SD (n) 22.1 AE 10.6, (94)</cell><cell>Body weight (kg)</cell><cell>Mean AE SD (n) 47.6 AE 12.6, (91)</cell><cell>Age at seizure onset (years) (n [%])</cell><cell>&lt;5 11 (12.0)</cell><cell>6 to 15 34 (37.0)</cell><cell>16 to 25 32 (34.8)</cell><cell>Above 25 15 (16.3)</cell><cell>Gender (n [%])</cell><cell>Male 77 (81.9)</cell><cell>Female 17 (18.1)</cell><cell>Seizure type (n [%])</cell><cell>Generalized tonic clonic seizures (GTCS) 68 (72.3)</cell><cell>Simple partial seizures (SPS) 2 (2.13)</cell><cell>Simple partial seizures with secondary 18 (19.1)</cell><cell>generalization (SPS sec. gen.)</cell><cell>Complex partial seizures (CPS) 0 (0.00)</cell><cell>Complex partial seizures with secondary 5 (5.32)</cell><cell>generalization (CPS sec.gen.)</cell><cell>Others 1 (1.06)</cell><cell>Seizure control (n [%])</cell><cell>No seizure 57 (60.6)</cell><cell>Recurrent seizure 37 (39.4)</cell><cell>Dose and drug-level parameters maintenance dose ((mg/day)/kg)</cell><cell>Median (range), n 4.95 (2.50-12.5), 78</cell><cell>Serum drug levels (mg/L)</cell><cell>Median (range), n 12.02 (3.8-24.5), 64</cell><cell>Dose-corrected serum drug levels ([mg/L]/[[mg/day]/kg])</cell><cell>2.42 (1.00-6.80), 62 Median (range), n</cell><cell>SD, standard deviation.</cell></row><row><cell cols="9">742 CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">ª 2016 John Wiley &amp; Sons Ltd</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>P corrected value = 0.022, OR = 2.72, 95% CI = 1.39-5.35)</s><s>only.</s><s>Diplotype analysis of significant GABRA1 haplotypes further revealed significant overrepresentation of rs12658835|rs7735530 (AG/AG: P corrected value = 0.0349, OR = 3.75, 95% CI = 1.36-11.05)</s><s>and rs12658835| rs7735530|rs7732641 (AGC/AGC: P corrected value = 0.0349, OR = 3.22, 95% CI = 1.20-9.10) in patients with "recurrent seizures" (Table</s></p></div></figDesc><table /><note><p><s>34, 95% CI = 1.11-4.94).</s><s>With respect to SCN1A, we observed significant association of a two-marker haplotype ª 2016 John Wiley &amp; Sons Ltd CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 743 rs6432860|rs3812718 (AC:</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2</head><label>2</label><figDesc><div><p><s>Association analysis of haplotypes and diplotypes with antiepileptic drug response</s></p></div></figDesc><table><row><cell cols="6">(A) Significantly associated haplotypes with antiepileptic drug response</cell><cell></cell><cell></cell></row><row><cell>Gene</cell><cell>SNPS</cell><cell></cell><cell></cell><cell cols="2">Haplotype</cell><cell>Recurrent seizures</cell><cell>No seizures</cell><cell>OR (95% CI)</cell><cell>P-value*</cell></row><row><cell>Phenytoin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GABRA1</cell><cell cols="2">rs12658835|rs7735530</cell><cell></cell><cell>AA</cell><cell></cell><cell>9.59</cell><cell>26.1</cell><cell>0.33 (0.13-0.83)</cell><cell>0.0060 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>AG</cell><cell></cell><cell>90.4</cell><cell>73.8</cell><cell>3.61 (1.57-8.28)</cell><cell>0.0060 a</cell></row><row><cell></cell><cell cols="2">rs2279020|rs2290732</cell><cell></cell><cell>AG</cell><cell></cell><cell>74.6</cell><cell>55.0</cell><cell>2.17 (1.16-4.07)</cell><cell>0.0078 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>GA</cell><cell></cell><cell>25.3</cell><cell>44.9</cell><cell>0.41 (0.21-0.82)</cell><cell>0.0078 a</cell></row><row><cell></cell><cell cols="2">rs7732641|rs2279020</cell><cell></cell><cell>CA</cell><cell></cell><cell>72.6</cell><cell>55.2</cell><cell>2.07 (0.68-6.32)</cell><cell>0.0170 c</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>TG</cell><cell></cell><cell>9.52</cell><cell>24.4</cell><cell>0.30 (0.12-0.77)</cell><cell>0.0105 a</cell></row><row><cell></cell><cell cols="2">rs7735530|rs7732641</cell><cell></cell><cell>AT</cell><cell></cell><cell>9.59</cell><cell>24.3</cell><cell>0.30 (0.12-0.78)</cell><cell>0.0118 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>GC</cell><cell></cell><cell>90.4</cell><cell>75.7</cell><cell>2.84 (1.21-6.66)</cell><cell>0.0118 a</cell></row><row><cell></cell><cell cols="3">rs12658835|rs7735530|rs7732641</cell><cell>AAT</cell><cell></cell><cell>9.72</cell><cell>24.8</cell><cell>0.33 (0.12-0.86)</cell><cell>0.0118 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>AGC</cell><cell></cell><cell>90.3</cell><cell>75.2</cell><cell>3.22 (1.46-7.08)</cell><cell>0.0118 a</cell></row><row><cell></cell><cell cols="3">rs7732641|rs2279020|rs2290732</cell><cell>CAG</cell><cell></cell><cell>74.3</cell><cell>55.0</cell><cell>2.33 (1.08-5.04)</cell><cell>0.0094 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>TGA</cell><cell></cell><cell>9.93</cell><cell>24.7</cell><cell>0.30 (0.12-0.77)</cell><cell>0.0140 b</cell></row><row><cell></cell><cell cols="3">rs7735530|rs7732641|rs2279020</cell><cell>ATG</cell><cell></cell><cell>9.59</cell><cell>24.3</cell><cell>0.30 (0.12-0.77)</cell><cell>0.0118 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>GCA</cell><cell></cell><cell>72.6</cell><cell>54.9</cell><cell>3.03 (1.28-7.19)</cell><cell>0.0159 c</cell></row><row><cell></cell><cell cols="3">rs7735530|rs7732641|rs2279020|</cell><cell>ATGA</cell><cell></cell><cell>10.0</cell><cell>25.2</cell><cell>0.30 (0.12-0.77)</cell><cell>0.0119 a</cell></row><row><cell></cell><cell>rs2290732</cell><cell></cell><cell></cell><cell>GCAG</cell><cell></cell><cell>74.3</cell><cell>54.2</cell><cell>1.36 (0.48-3.88)</cell><cell>0.0071 a</cell></row><row><cell></cell><cell cols="3">rs12658835|rs7735530|rs7732641|</cell><cell>AATG</cell><cell></cell><cell>9.59</cell><cell>24.6</cell><cell>0.30 (0.12-0.77)</cell><cell>0.0108 a</cell></row><row><cell></cell><cell>rs2279020</cell><cell></cell><cell></cell><cell>AGCA</cell><cell></cell><cell>72.6</cell><cell>54.5</cell><cell>2.90 (1.22-6.93)</cell><cell>0.0138 b</cell></row><row><cell></cell><cell cols="3">rs12658835|rs7735530|rs7732641|</cell><cell>AATGA</cell><cell></cell><cell>10.0</cell><cell>25.5</cell><cell>0.30 (0.12-0.77)</cell><cell>0.0109 a</cell></row><row><cell></cell><cell cols="2">rs2279020|rs2290732</cell><cell></cell><cell>AGCAG</cell><cell></cell><cell>74.3</cell><cell>53.7</cell><cell>2.34 (1.11-4.94)</cell><cell>0.0061 a</cell></row><row><cell>SCN1A</cell><cell cols="2">rs6432860|rs3812718</cell><cell></cell><cell>AC</cell><cell></cell><cell>40.5</cell><cell>19.3</cell><cell>2.72 (1.39-5.35)</cell><cell>0.0015 a</cell></row><row><cell>Carbamazepine</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>STX1A</cell><cell cols="2">rs867500|rs4363087</cell><cell></cell><cell>GT</cell><cell></cell><cell>54.9</cell><cell>39.4</cell><cell>1.97 (1.24-3.13)</cell><cell>0.0048 d</cell></row><row><cell>Phenobarbitone</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ALDH5A1</cell><cell cols="2">rs2247845|rs1054899</cell><cell></cell><cell>TC</cell><cell></cell><cell>13.6</cell><cell>38.1</cell><cell>0.25 (0.04-1.34)</cell><cell>0.0419 e</cell></row><row><cell cols="6">(B) Significantly associated diplotypes in phenytoin group of patients</cell><cell></cell><cell></cell></row><row><cell cols="2">Phenotypic groups</cell><cell>Gene</cell><cell>Diplotype</cell><cell></cell><cell></cell><cell>Recurrent seizures (n%)</cell><cell>No seizures (n%)</cell><cell>OR (95% CI)</cell><cell>P-value*</cell></row><row><cell cols="2">Phenytoin drug response</cell><cell>GABRA1</cell><cell cols="2">rs12658835|rs7735530</cell><cell>AG</cell><cell>29 (78.4)</cell><cell>28 (49.1)</cell><cell>3.75 (1.36-11.0)</cell><cell>0.0046 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs2279020|rs2290732</cell><cell>AG</cell><cell>19 (51.3)</cell><cell>17 (29.8)</cell><cell>2.48 (0.96-6.41)</cell><cell>0.0359 b</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs7732641|rs2279020</cell><cell>CA</cell><cell>19 (51.3)</cell><cell>17 (29.8)</cell><cell>2.48 (0.96-6.41)</cell><cell>0.0359 b</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs7735530|rs7732641</cell><cell>GC</cell><cell>29 (78.4)</cell><cell>32 (56.1)</cell><cell>2.83 (1.02-8.37)</cell><cell>0.0273 b</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs12658835|rs7735530|</cell><cell>AGC</cell><cell>28 (75.7)</cell><cell>28 (49.1)</cell><cell>3.22 (1.20-9.10)</cell><cell>0.0104 a</cell></row><row><cell></cell><cell></cell><cell></cell><cell>rs7732641</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs7735530|rs7732641|</cell><cell>GCA</cell><cell>19 (51.3)</cell><cell>17 (29.8)</cell><cell>2.48 (0.96-6.41)</cell><cell>0.0359 b</cell></row><row><cell></cell><cell></cell><cell></cell><cell>rs2279020</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs12658835|rs7735530|</cell><cell>AGCA</cell><cell>19 (51.3)</cell><cell>17 (29.8)</cell><cell>2.48 (0.96-6.41)</cell><cell>0.0359 b</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">rs7732641|rs2279020</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>SCN1A</cell><cell cols="2">rs6432860|rs3812718</cell><cell>AC</cell><cell>7 (18.9)</cell><cell>2 (3.51)</cell><cell>6.42 (1.10-65.8)</cell><cell>0.0131</cell></row></table><note><p><s>a SNPs with P &lt; 0.05 were included for haplotype analysis, haplotype with minimum frequency &lt;0.05 was excluded from the study, P-values in bold remained significant after correction, *FDR corrected P-values, a 0.022, b 0.023, c 0.025, d 0.050, e 0.0189; OR, odds ratio; CI, confidence interval.</s><s>Haplotypes which withstood FDR correction were included for diplotype analysis.</s><s>P-values in bold remained significant after correction.</s><s>*FDR corrected P-values a 0.0349, b 0.0359; OR, odds ratio; CI, confidence interval.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3</head><label>3</label><figDesc><div><p><s>Effects of SCN1A diplotypes, genotypes, and model on PHT maintenance doses, maximum doses, and corresponding adjusted serum PHT concentrations Data were represented as n (mean rank) number and mean rank, P-values for diplotype and dominant model were calculated by Mann-Whitney U-test and for genotype were calculated by Kruskal-Wallis test.</s><s>No significant association was observed.,</s><s>AC (À): AC diplotype present, AC (+): AC diplotype absent.</s><s>P-values in bold are significantly associated and &lt; 0.05.</s><s>), and SNAP25 (rs3787283) were significantly associated with drug response, but none could withstand corrections for multiple comparisons (Table</s></p></div></figDesc><table><row><cell></cell><cell cols="2">SCN1A_ rs6432860</cell><cell></cell><cell cols="2">SCN1A_ rs3812718</cell><cell></cell></row><row><cell>Genotypic</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n (mean</cell><cell></cell></row><row><cell>Maintenance</cell><cell>Genotypic</cell><cell>n (mean rank)</cell><cell>P-value</cell><cell>Genotypic</cell><cell>rank)</cell><cell>P-value</cell></row><row><cell>Dose corrected by weight (mg/day per kg)</cell><cell>GG</cell><cell>46 (41.0)</cell><cell>0.166</cell><cell>TT</cell><cell>23 (41.2)</cell><cell>0.171</cell></row><row><cell></cell><cell>GA</cell><cell>26 (40.8)</cell><cell></cell><cell>CT</cell><cell>39 (42.4)</cell><cell></cell></row><row><cell></cell><cell>AA</cell><cell>6 (22.7)</cell><cell></cell><cell>CC</cell><cell>16 (30.1)</cell><cell></cell></row><row><cell>Dug levels corrected by dose (mg/L per mg/kg)</cell><cell>GG</cell><cell>34 (33.9)</cell><cell>0.208</cell><cell>TT</cell><cell>15 (34.4)</cell><cell>0.691</cell></row><row><cell></cell><cell>GA</cell><cell>22 (30.9)</cell><cell></cell><cell>CT</cell><cell>33 (31.4)</cell><cell></cell></row><row><cell></cell><cell>AA</cell><cell>6 (19.8)</cell><cell></cell><cell>CC</cell><cell>14 (28.6)</cell><cell></cell></row><row><cell>Maximum</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose corrected by weight (mg/day per kg)</cell><cell>GG</cell><cell>49 (44.9)</cell><cell>0.867</cell><cell>TT</cell><cell>25 (45.5)</cell><cell>0.629</cell></row><row><cell></cell><cell>GA</cell><cell>30 (45.2)</cell><cell></cell><cell>CT</cell><cell>14 (46.1)</cell><cell></cell></row><row><cell></cell><cell>AA</cell><cell>9 (40.2)</cell><cell></cell><cell>CC</cell><cell>19 (39.5)</cell><cell></cell></row><row><cell>Dug levels corrected by dose (mg/L per mg/kg)</cell><cell>GG</cell><cell>35 (38.8)</cell><cell>0.042</cell><cell>TT</cell><cell>16 (38.4)</cell><cell>0.472</cell></row><row><cell></cell><cell>GA</cell><cell>24 (33.5)</cell><cell></cell><cell>CT</cell><cell>35 (34.9)</cell><cell></cell></row><row><cell></cell><cell>AA</cell><cell>9 (20.3)</cell><cell></cell><cell>CC</cell><cell>17 (30.1)</cell><cell></cell></row><row><cell></cell><cell cols="2">SCN1A_ rs6432860</cell><cell></cell><cell>SCN1A_ rs3812718</cell><cell></cell><cell></cell></row><row><cell>Dominant model</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Maintenance</cell><cell>Dominant model</cell><cell>n (mean rank)</cell><cell>P-value</cell><cell>Dominant model</cell><cell>n (mean rank)</cell><cell>P-value</cell></row><row><cell>Dose corrected by weight (mg/day per kg)</cell><cell>GG</cell><cell>46 (41.0)</cell><cell>0.489</cell><cell>TT</cell><cell>23 (41.2)</cell><cell>0.673</cell></row><row><cell></cell><cell>GA+AA</cell><cell>32 (37.4)</cell><cell></cell><cell>CT+CC</cell><cell>55 (38.8)</cell><cell></cell></row><row><cell>Dug levels corrected by dose (mg/L per mg/kg)</cell><cell>GG</cell><cell>34 (33.9)</cell><cell>0.246</cell><cell>TT</cell><cell>15 (34.4)</cell><cell>0.475</cell></row><row><cell></cell><cell>GA+AA</cell><cell>28 (28.6)</cell><cell></cell><cell>CT+CC</cell><cell>47 (30.6)</cell><cell></cell></row><row><cell>Maximum</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose corrected by weight (mg/day per kg)</cell><cell>GG</cell><cell>49 (44.9)</cell><cell>0.883</cell><cell>TT</cell><cell>25 (45.5)</cell><cell>0.810</cell></row><row><cell></cell><cell>GA+AA</cell><cell>39 (44.0)</cell><cell></cell><cell>CT+CC</cell><cell>63 (44.1)</cell><cell></cell></row><row><cell>Dug levels corrected by dose (mg/L per mg/kg)</cell><cell>GG</cell><cell>35 (38.8)</cell><cell>0.065</cell><cell>TT</cell><cell>16 (38.4)</cell><cell>0.362</cell></row><row><cell></cell><cell>GA+AA</cell><cell>33 (29.9)</cell><cell></cell><cell>CT+CC</cell><cell>52 (33.3)</cell><cell></cell></row><row><cell></cell><cell cols="3">SCN1A_rs6432860|rs3812718</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diplotype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Maintenance</cell><cell cols="2">Diplotype</cell><cell cols="2">n (mean rank)</cell><cell>P-value</cell><cell></cell></row><row><cell>Dose corrected by weight (mg/day per kg)</cell><cell cols="2">AC (+)</cell><cell>6 (22.7)</cell><cell></cell><cell>0.06</cell><cell></cell></row><row><cell></cell><cell cols="2">AC (À)</cell><cell>72 (40.9)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dug levels corrected by dose (mg/L per mg/kg)</cell><cell cols="2">AC (+)</cell><cell>6 (19.8)</cell><cell></cell><cell>0.1</cell><cell></cell></row><row><cell></cell><cell cols="2">AC (À)</cell><cell>56 (32.7)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Maximum</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose corrected by weight (mg/day per kg)</cell><cell cols="2">AC (+)</cell><cell>9 (40.2)</cell><cell></cell><cell>0.6</cell><cell></cell></row><row><cell></cell><cell cols="2">AC (À)</cell><cell>79 (45.0)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dug levels corrected by dose (mg/L per mg/kg)</cell><cell cols="2">AC (+)</cell><cell>9 (20.3)</cell><cell></cell><cell>0.02</cell><cell></cell></row><row><cell></cell><cell cols="2">AC (À)</cell><cell>59 (36.7)</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>ª 2016 John Wiley &amp; Sons Ltd CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 745 rs867500, rs4363087</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4</head><label>4</label><figDesc><div><p><s>A comparative summary of pharmacogenetic studies exploring association analysis of SCN1A and GABRA1 variants with drug response and therapeutic optimization parameters (dose and drug levels) in patients treated with first-generation AEDs</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>Significant association of</cell><cell>rs3812718 with</cell><cell>maximum dose in CBZ</cell><cell>as well as PHT patients</cell><cell>(Trend: A&gt;AG&gt;GG)</cell><cell></cell><cell>Significant association of</cell><cell>rs3812718 with PHT</cell><cell>serum levels at</cell><cell>maintenance dose</cell><cell>(Trend: A&gt;AG&gt;GG)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>AA genotype was</cell><cell>associated with drug</cell><cell>resistance in CBZ</cell><cell>patients. Trend for</cell><cell>maximum or</cell><cell>maintenance dose of</cell><cell>CBZ: AA&gt;GA+GG</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(continued)</cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell>425 PHT</cell><cell>281 CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>168</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>221 117 drug</cell><cell>responsive</cell><cell>104 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>471 272 drug</cell><cell>responsive</cell><cell>199 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell>rs590478,</cell><cell>rs8191987,</cell><cell>rs3812718,</cell><cell>rs2126152</cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs1020853, rs2298771,</cell><cell>rs3812718, rs10188577,</cell><cell>rs4667866, rs13405797,</cell><cell>rs1461197, rs2169312</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell>PHT CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>PHT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>Dose Maximum dose:</cell><cell>Maximum dose to</cell><cell>which patients were</cell><cell>exposed to during</cell><cell>their regular</cell><cell>treatment.</cell><cell>Dose Maintenance dose:</cell><cell>Dose which has not</cell><cell>been changed for two</cell><cell>or more consecutive</cell><cell>visits in the history of</cell><cell>the patient's treatment.</cell><cell>Maximum dose:</cell><cell>Maximum dose to</cell><cell>which patients were</cell><cell>exposed to during their</cell><cell>regular treatment.</cell><cell>Drug response Drug</cell><cell>responsive: No seizures</cell><cell>for a minimum of one</cell><cell>year after receiving</cell><cell>AED(s). Drug resistant:</cell><cell>Uncontrolled seizures</cell><cell>over a year despite</cell><cell>attempts to treat with</cell><cell>three or more different</cell><cell>AEDs.</cell><cell>Dose Maintenance dose:</cell><cell>Latest dose in the drug-</cell><cell>responsive patient.</cell><cell>Maximum dose: Highest</cell><cell>dose during the study</cell><cell>period.</cell><cell>Drug response Drug</cell><cell>responsive: No seizure</cell><cell>for at least a year up to</cell><cell>the date of recruitment</cell><cell>on a stable dose of AED</cell><cell>treatment. Drug resistant:</cell><cell>An average of one seizure</cell><cell>or more per month over</cell><cell>the preceding year,</cell><cell>despite treatment with</cell><cell>two or more AEDs at</cell><cell>therapeutic dosages</cell><cell>and/or serum drug</cell><cell>concentrations.</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell>Dose</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>Dose</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell>Caucasian</cell><cell>(European)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Japanese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Han Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell>Tate et al.</cell><cell>2005 [34]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Tate et al.</cell><cell>2006 [41]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Abe et al.</cell><cell>2008 [39]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Kwan et al.</cell><cell>2008 [42]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>ª 2016 John Wiley &amp; Sons Ltd CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 747</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>No association</cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GG genotype and G allele</cell><cell>were associated with</cell><cell>drug resistance.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell>369</cell><cell></cell><cell>400 200 drug</cell><cell>responsive 200</cell><cell>drug resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>336 219 drug</cell><cell>responsive 117</cell><cell>drug resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>381 259 drug</cell><cell>responsive 122</cell><cell>drug resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell>rs3812718</cell><cell></cell><cell>1 SNP</cell><cell>(Nonsynonymous</cell><cell>variant, exon 16)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2279020</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell>SCN1A</cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell>CBZ</cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell>FE</cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>Dose Maintenance dose</cell><cell></cell><cell>Drug response Drug</cell><cell>responsive: In patients</cell><cell>treated with single AED,</cell><cell>no seizures for at least</cell><cell>one year, up to the date</cell><cell>of the last follow-up visit.</cell><cell>Drug resistant: Occurrence</cell><cell>of at least four unprovoked</cell><cell>seizures over the year</cell><cell>before recruitment with</cell><cell>trials of more than two</cell><cell>appropriate AEDs at</cell><cell>maximal tolerated doses</cell><cell>or patients who had</cell><cell>undergone surgical</cell><cell>treatment for seizure</cell><cell>control.</cell><cell>Drug response Drug</cell><cell>responsive: No seizures</cell><cell>for at least one year from</cell><cell>the last follow-up visit.</cell><cell>Drug resistant: Occurrence</cell><cell>of at least four seizures</cell><cell>over a period of one year</cell><cell>with three appropriate</cell><cell>AEDs at maximum</cell><cell>tolerated doses or patients</cell><cell>who had undergone</cell><cell>surgery for seizure control.</cell><cell>Drug response Drug</cell><cell>responsive: No seizures for</cell><cell>at least one year from the</cell><cell>last follow-up visit. Drug</cell><cell>resistant: Occurrence of at</cell><cell>least four seizures over a</cell><cell>period of one year with</cell><cell>three appropriate AEDs at</cell><cell>maximum tolerated doses</cell><cell>or patients who had</cell><cell>undergone surgery for</cell><cell>seizure control.</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell>Dose</cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell>Caucasian</cell><cell>(European)</cell><cell>Asian</cell><cell>(Korean)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(North Indian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(North Indian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell>Zimprich et al. 2008 [36]</cell><cell></cell><cell>Jang et al. 2009 [43]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Lakhan et al. 2009 [44]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Kumari et al. 2010 [32]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>5</cell><cell></cell><cell>6</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>7</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>(continued) 748 CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 ª 2016 John Wiley &amp; Sons Ltd</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Interactive association of</cell><cell>rs12658835 and</cell><cell>rs35166395 (GABRA1),</cell><cell>rs2228622 (EAAT3), and</cell><cell>rs2304725 (GAT3) with</cell><cell>drug resistance</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(continued)</cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell>289 178 drug</cell><cell>responsive 111</cell><cell>drug resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>400 200 drug</cell><cell>responsive</cell><cell>200 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>883 482 drug</cell><cell>responsive</cell><cell>401 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell>rs2298771, rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771 (SCN1A);</cell><cell>rs12658835,</cell><cell>rs35166395</cell><cell>(GABRA1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A,</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>FE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>Drug response Drug</cell><cell>responsive: No seizures for</cell><cell>at least one year from the</cell><cell>last follow-up visit. Drug</cell><cell>resistant: Occurrence of</cell><cell>at least four seizures over</cell><cell>a period of one year with</cell><cell>three appropriate AEDs at</cell><cell>maximum tolerated doses</cell><cell>or patients who had</cell><cell>undergone surgery for</cell><cell>seizure control.</cell><cell>Drug response</cell><cell>Drug responsive: No</cell><cell>seizure for at least one</cell><cell>year, up to the date of</cell><cell>the last follow-up visit. Drug</cell><cell>resistant: Occurrence of at</cell><cell>least four unprovoked</cell><cell>seizures over the year</cell><cell>before recruitment with</cell><cell>trials of more than two</cell><cell>appropriate AEDs at</cell><cell>maximal tolerated doses</cell><cell>or patients who had</cell><cell>undergone surgery for</cell><cell>seizure control.</cell><cell>Drug response</cell><cell>Drug responsive: No</cell><cell>seizure for at least the</cell><cell>previous two years.</cell><cell>Drug resistant:</cell><cell>Persistence of seizures</cell><cell>during the previous two</cell><cell>years with a frequency</cell><cell>of at least one seizure/month,</cell><cell>despite current or previous</cell><cell>treatment with three or more</cell><cell>appropriate AEDs, either</cell><cell>alone or in combination, and</cell><cell>at the highest tolerated dose.</cell><cell>For patients who had</cell><cell>undergone epilepsy surgery,</cell><cell>drug resistance was defined</cell><cell>as at least one seizure/month</cell><cell>during the two years that</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>and</cell><cell>dose</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell>Caucasian</cell><cell>(Spanish)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Korean)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Caucasian</cell><cell>(Italian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell>Sanchez et al. 2010 [45]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Kim et al. 2011 [33]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Manna et al. 2011 [38]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>11</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>ª 2016 John Wiley &amp; Sons Ltd CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 749</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718 A allele and</cell><cell>AA genotype were</cell><cell>associated with</cell><cell>higher CBZ dosages and</cell><cell>lower ln(concentration/</cell><cell>dose ratios)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association with drug</cell><cell>response, association of</cell><cell>rs3812718 with dose in</cell><cell>drug-responsive patients</cell><cell>(Trend: A&gt;AG&gt;GG)</cell><cell></cell><cell></cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>583 306 drug</cell><cell>responsive</cell><cell>277 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>234</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>147 82 drug</cell><cell>responsive</cell><cell>65 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771, rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>VP</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>preceded surgery, provided</cell><cell>that at the time of surgery</cell><cell>the patient met the above</cell><cell>criteria for pharmacoresistance.</cell><cell>Dose</cell><cell>Dose ratio: Prescribed daily</cell><cell>dose (PDD)/defined daily dose</cell><cell>(DDD) ratios, where DDD is the</cell><cell>average maintenance daily</cell><cell>dose in adults.</cell><cell>Drug response</cell><cell>Drug responsive: No seizure</cell><cell>for at least one year during</cell><cell>monotherapy.</cell><cell>Drug resistant: Occurrence</cell><cell>of seizures over a period of</cell><cell>one year during treatment</cell><cell>with monotherapy at</cell><cell>maximally tolerated</cell><cell>therapeutic dosages.</cell><cell>Dose</cell><cell>Maintenance dose: Dosage</cell><cell>that had not been changed</cell><cell>for at least one year under</cell><cell>good compliance and good</cell><cell>seizure control (freedom</cell><cell>from seizures for a minimum</cell><cell>of three times the longest</cell><cell>pre-intervention interseizure</cell><cell>interval (determined from</cell><cell>seizures occurring within the</cell><cell>past 12 months) or 12 months,</cell><cell>whichever was</cell><cell>longer.</cell><cell>Dose and drug levels</cell><cell>Concentration/dose ratio</cell><cell>(CDR): Mean steady-state</cell><cell>serum concentration/</cell><cell>daily dose.</cell><cell>Drug response</cell><cell>Drug responsive: No seizure</cell><cell>for at least one year of</cell><cell>treatment with CBZ.</cell><cell>Drug resistant: Occurrence</cell><cell>of at least four seizures over</cell><cell>one year of treatment</cell><cell>with CBZ.</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Malaysian</cell><cell>and</cell><cell>Hong Kong</cell><cell>!Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian (Han</cell><cell>Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Caucasian</cell><cell>(Macedonian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Haerian et al. 2012 [46]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hung et al. 2012 [47]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Sterjev et al. 2012 [48]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>13</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>14</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>(continued) 750 CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 ª 2016 John Wiley &amp; Sons Ltd</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Poor response was</cell><cell>associated with</cell><cell>rs2298771 AG+GG from</cell><cell>3 months to 15 months</cell><cell>of follow-up.</cell><cell>Maintenance doses and</cell><cell>serum levels of CBZ in</cell><cell>carriers of the</cell><cell>rs3812718 AA genotype</cell><cell>of were significantly</cell><cell>higher than those of GG</cell><cell>genotype from 3 to</cell><cell>12 months of follow-up,</cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell>(continued)</cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>448</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>441 201 drug</cell><cell>responsive</cell><cell>240 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1504 702 drug</cell><cell>responsive</cell><cell>802 drug</cell><cell>resistant</cell></row><row><cell>Genetic</cell><cell>variants</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771, rs3812718,</cell><cell>rs4667869, rs11692675,</cell><cell>rs1020853, rs10497275,</cell><cell>rs7577411, rs1813502</cell><cell>(SCN1A); rs12658835,</cell><cell>rs2290732, rs35166395</cell><cell>(GABRA1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2279020</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs10182473, rs1020853,</cell><cell>rs2298771, rs10930195</cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A,</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ VP</cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>FE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>JME,</cell><cell>MTLE-HS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>Dose</cell><cell>Maintenance dose: Dose that</cell><cell>has not been changed for</cell><cell>two or more consecutive</cell><cell>visits in the history of the</cell><cell>patient's treatment.</cell><cell>Dose ratio: Prescribed daily</cell><cell>dose (PDD)/defined daily dose</cell><cell>(DDD) ratios, where DDD is</cell><cell>the average maintenance</cell><cell>daily dose in adults.</cell><cell>Dose and drug levels</cell><cell>Index of comparison: CBZ</cell><cell>daily dose/CBZ plasma level</cell><cell>Drug response</cell><cell>Good response: Seizure free</cell><cell>(SF) during 24-month follow-up</cell><cell>period; poor response:</cell><cell>combination of 75%, 50-75%,</cell><cell>and &lt;50% SF during 24-month</cell><cell>follow-up period.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug response</cell><cell>Drug responsive: No seizure</cell><cell>for at least one year on AED</cell><cell>therapy. Drug resistant:</cell><cell>Unresponsive to at least two</cell><cell>monotherapy trials and one</cell><cell>duo-therapy trial, each of at</cell><cell>least six-month duration, and</cell><cell>had seizure frequency of at</cell><cell>least 12 per year for at</cell><cell>least two years.</cell><cell>Drug response</cell><cell>Drug responsive: No seizure</cell><cell>for at least one year during</cell><cell>treatment with monotherapy.</cell><cell>Drug resistant: Occurrence of</cell><cell>seizures over a period of one</cell><cell>year while undergoing</cell><cell>treatment with monotherapy</cell><cell>at maximally</cell><cell>tolerated therapeutic dosages.</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Han Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(South Indian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Malaysian,</cell><cell>Hong Kong</cell><cell>Chinese)</cell></row><row><cell>Author and</cell><cell>year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Zhou et al. 2012 [49]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Balan et al. 2013 [50]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Haerian et al. 2013 [51]</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>15</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>16</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>17</cell><cell></cell><cell></cell></row><row><cell cols="7">ª 2016 John Wiley &amp; Sons Ltd</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="12">CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 751</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>Interactive association of</cell><cell>rs6883877 (GABRA1),</cell><cell>GABRA2 (rs511310), and</cell><cell>GABRA3 (rs4828696) with</cell><cell>drug resistance.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(continued)</cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell>721 349 drug</cell><cell>responsive</cell><cell>371 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>484 294 drug</cell><cell>responsive</cell><cell>170 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>83 59 drug</cell><cell>response</cell><cell>34 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell>Gene wide tagging</cell><cell>SNPs (including</cell><cell>rs6883877, rs1157122,</cell><cell>rs6892782, rs10068980)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>Drug response</cell><cell>Drug responsive: No seizure</cell><cell>for a minimum of three times</cell><cell>the longest pre-intervention</cell><cell>interseizure interval</cell><cell>(determined from</cell><cell>seizures occurring within the</cell><cell>past 12 months) or 12 months,</cell><cell>whichever was longer.</cell><cell>Drug resistant: Failure to</cell><cell>achieve seizure freedom with</cell><cell>at least two appropriately</cell><cell>prescribed AEDs under</cell><cell>maximum</cell><cell>tolerated doses</cell><cell>Drug response:</cell><cell>Drug responsive: No seizure</cell><cell>for at least one year from</cell><cell>the last follow-up visit.</cell><cell>Drug resistant: Occurrence of</cell><cell>at least four seizures over a</cell><cell>period of one year with three</cell><cell>appropriate AEDs at maximum</cell><cell>tolerated doses or patients</cell><cell>who had undergone surgery</cell><cell>for seizure control.</cell><cell>Drug response</cell><cell>Drug responsive: Response</cell><cell>to treatment in a one-year</cell><cell>study.</cell><cell>Drug resistant: Poor</cell><cell>response to treatment in</cell><cell>a 1-year study.</cell><cell>Dose</cell><cell>Maintenance dose</cell><cell>Dose and Drug levels</cell><cell>Index of comparison:</cell><cell>Steady-state plasma</cell><cell>concentrations of CBZ were</cell><cell>adjusted by the dose and</cell><cell>body weight</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell>Asian</cell><cell>(Han Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(North Indian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell>Hung et al. 2013 [52]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Kumari et al. 2013 [37]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yun et al. 2013 [40]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>18</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>19</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>20</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="13">752 CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="5">ª 2016 John Wiley &amp; Sons Ltd</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>rs2298771 G allele and</cell><cell>GG+GA were associated</cell><cell>with nonseizure free</cell><cell>patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs10188577 CT was</cell><cell>associated with drug</cell><cell>resistance</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association with drug</cell><cell>response; rs3812718 AA</cell><cell>showed significantly</cell><cell>lower levels of plasma</cell><cell>CBZ compared to GG.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718 A allele and</cell><cell>rs3812718A-rs2298771A</cell><cell>haplotype were</cell><cell>associated with a higher</cell><cell>(continued)</cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell>351 194 seizure</cell><cell>free 157</cell><cell>nonseizure free</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>519 161 drug</cell><cell>responsive</cell><cell>358 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>145 99 drug</cell><cell>responsive</cell><cell>46 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>166</cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell>rs3812718, rs2298771</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs1813502, rs1461195,</cell><cell>rs1020853, rs6432860,</cell><cell>rs1972445, rs10188577,</cell><cell>rs7607543, rs11686142,</cell><cell>rs1461197</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771, rs3812718</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771, rs3812718</cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell>FE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>Drug response</cell><cell>Seizure free: 100% decrease</cell><cell>in the proportion of seizures</cell><cell>between first three and last</cell><cell>three months of the one-year</cell><cell>study.</cell><cell>Nonseizure free: Less than</cell><cell>100% decrease in the</cell><cell>proportion of seizures</cell><cell>between first three and last</cell><cell>three months of the</cell><cell>one-year study.</cell><cell>Drug response</cell><cell>Drug responsive: No seizure</cell><cell>for at least a year, up to the</cell><cell>date of the last follow-up</cell><cell>visit, in patients with epilepsy</cell><cell>treated with sodium channel</cell><cell>blocking AEDs.</cell><cell>Drug resistant: Occurrence of</cell><cell>at least four seizures over the</cell><cell>year before recruitment with</cell><cell>trials of two or more sodium</cell><cell>channel blocking AEDs at</cell><cell>maximal tolerated doses.</cell><cell>Drug response</cell><cell>Drug responsive: Seizure free</cell><cell>for at least one year during</cell><cell>monotherapy treatment.</cell><cell>Drug resistant: Occurrence of</cell><cell>at least four seizures over a</cell><cell>period of one year of</cell><cell>monotherapy treatment.</cell><cell>Dose and drug levels</cell><cell>Concentration/dose ratios</cell><cell>(CDRs): Maintenance dose-</cell><cell>adjusted concentrations of</cell><cell>CBZ, CBZE and CBZD and CBZE:</cell><cell>CBZ, CBZD: CBZ, and CBZD:</cell><cell>CBZE ratios were used as</cell><cell>parameters for the evaluation</cell><cell>of CBZ metabolism.</cell><cell>Dose</cell><cell>Maintenance dose: Dose that</cell><cell>had not been changed for at</cell><cell>least one year in association</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell>Asian</cell><cell>(Han Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Caucasian</cell><cell>(Australian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Caucasian</cell><cell>(Kosovo)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Han Chinese)</cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell>Wang et al. 2014 [53]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yip et al. 2014 [54]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Daci et al. 2015 [55]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Ma et al. 2015 [56]</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>21</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>22</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>23</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>24</cell><cell></cell><cell></cell></row></table><note><p><s>ª 2016 John Wiley &amp; Sons Ltd CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 753</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued)</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>adjusted CBZ</cell><cell>maintenance dose and</cell><cell>a lower CBZ natural</cell><cell>logarithmic</cell><cell>concentration-dose</cell><cell>ratio (lnCDR).</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No association</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GABRA1 diplotype</cell><cell>rs12658835A-</cell><cell>rs7735530G/rs12658835A-</cell><cell>rs7735530G and SCN1A</cell><cell>diplotype rs6432860A-</cell><cell>rs3812718C/ rs6432860A-</cell><cell>rs3812718C were</cell><cell>associated with recurrent</cell><cell>seizures in patients</cell><cell>treated with PHT</cell><cell>(continued)</cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>391 235 drug</cell><cell>responsive</cell><cell>156 drug</cell><cell>resistant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>379 225 No</cell><cell>seizure 154</cell><cell>Recurrent</cell><cell>seizures 94</cell><cell>on</cell><cell>PHT 168 on</cell><cell>CBZ 85 on VP</cell><cell>32 on PB</cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs2298771</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs3812718 (SCN1A);</cell><cell>rs2279020 (GABRA1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>rs6735544, rs1381105,</cell><cell>rs4667869, rs10188577,</cell><cell>rs8191987, rs3812718,</cell><cell>rs6432860, rs10197430,</cell><cell>rs2298771, rs10497276,</cell><cell>rs1813502 (SCN1A);</cell><cell>rs11575999,rs11576001,</cell><cell>rs12658835, rs35166395,</cell><cell>rs7735530, rs12188495,</cell><cell>rs7732641, rs1350372,</cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A,</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCN1A,</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CBZ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>drugs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>PHT</cell><cell>CBZ</cell><cell>VP PB</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Various</cell><cell>types</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>with good compliance and</cell><cell>seizure control. Good seizure</cell><cell>control was defined as freedom</cell><cell>from seizures for a minimum of</cell><cell>3-fold the longest pre-intervention</cell><cell>interseizure interval (determined</cell><cell>from seizures occurring within</cell><cell>the past 12 months) or</cell><cell>12 months, whichever</cell><cell>was longer.</cell><cell>Dose and Drug levels</cell><cell>Concentration/dose ratios</cell><cell>(CDRs): Plasma CBZ Css/CBZ</cell><cell>maintenance dose. The CBZE:</cell><cell>CBZ ratio (at trough).</cell><cell>Dose</cell><cell>Minimum Dose, Maximum Dose,</cell><cell>Mean Dose</cell><cell>Drug levels</cell><cell>CBZ, CBZ-E</cell><cell>Dose and Drug levels</cell><cell>CBZ concentration-dose</cell><cell>Drug response</cell><cell>Drug responsive: Complete</cell><cell>seizure freedom for a minimum</cell><cell>of three times the longest</cell><cell>interseizure interval before</cell><cell>treatment, or one year</cell><cell>(the longer).</cell><cell>Drug resistant: Failure of</cell><cell>continuous seizure freedom</cell><cell>after adequate treatment of</cell><cell>two tolerated and</cell><cell>appropriately used AEDs</cell><cell>(monotherapy or in</cell><cell>combination).</cell><cell>Drug response</cell><cell>No seizure: Patients who</cell><cell>remained seizure free in the</cell><cell>last ten months, despite</cell><cell>appropriate AED treatment, after</cell><cell>attaining steady-state AED levels</cell><cell>in the first two months of</cell><cell>the study.</cell><cell>Recurrent seizures: Patients with</cell><cell>one or more seizures in the last</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drug</cell><cell>response</cell><cell>Dose Drug</cell><cell>levels</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Iranian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(Han Chinese)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Asian</cell><cell>(North Indian)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Namazi et al. 2015 [57]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Zhou et al. 2015 58]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Present study</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>25</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>26</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>27</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_14"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Continued) , antiepileptic drug, CBZ, carbamazepine, CBZE, carbamazepine-10,11-epoxide, CBZD, carbamazepine-10,11-trans dihydrodiol, Css, steady-state drug concentration, FE, focal epilepsy, JME, juvenile myoclonic epilepsy, MTLE-HS, mesial temporal lobe epilepsy with hippocampal sclerosis, PB, phenobarbitone, PHT, phenytoin, VP, valproate.</s></p></div></figDesc><table><row><cell>Association with SCN1A/</cell><cell>GABRA1 variants</cell><cell>monotherapy. SCN1A</cell><cell>diplotype rs6432860A-</cell><cell>rs3812718C/rs6432860A-</cell><cell>rs3812718C was also</cell><cell>associated with lower</cell><cell>dose-adjusted drug levels</cell><cell>in patients treated with</cell><cell>PHT monotherapy.</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total No. of</cell><cell>patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genetic</cell><cell>variants</cell><cell>rs1157122, rs2279020,</cell><cell>rs2290732, rs998754</cell><cell>(GABRA1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SCN1A/</cell><cell>GABRA1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>AEDs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Epilepsy</cell><cell>syndrome</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Definition of outcome</cell><cell>ten months despite appropriate</cell><cell>AED treatment, after attaining</cell><cell>steady-state AED levels in the</cell><cell>first two months of the study.</cell><cell>Dose</cell><cell>Maintenance dose,</cell><cell>Maximum dose</cell><cell>Dose and Drug levels</cell><cell>Concentration/dose ratios (CDRs):</cell><cell>AED Css/AED</cell><cell>maintenance dose, AED Css/AED</cell><cell>maximum dose.</cell></row><row><cell>Outcome</cell><cell>variable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Population</cell><cell>(Ethnicity)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Author and</cell><cell>year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>AED</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2016 John Wiley &amp; Sons Ltd</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="744">CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 ª 2016 John Wiley &amp; Sons Ltd SCN1A and GABRA1 Variants in Phenytoin Response R. Baghel et al.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="746">CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 ª 2016 John Wiley &amp; Sons Ltd SCN1A and GABRA1 Variants in Phenytoin Response R. Baghel et al.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2016 John Wiley &amp; Sons Ltd CNS Neuroscience &amp; Therapeutics 22 (2016) 740-757 755</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors express their thanks to patients and their family members for participation in the study.</s><s>Authors also thank the funding agencies Indian Council of Medical Research (ICMR), Council of Scientific and Industrial Research (CSIR), and University Grants Commission (UGC) for fellowships and other financial support GAP0091 (ICMR) and BSC0123 (CSIR) Projects.</s><s>The authors are grateful to Prof. Samir K Brahmachari (CSIR-IGIB) and Prof. M. Gourie-Devi (IHBAS) for their vision and intellectual inputs, and Dr. Mitali Mukerji (CSIR-IGIB) and Dr Abhay Sharma (CSIR-IGIB) for their unconditional support.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest</head><p><s>The authors declare no conflict of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head><p><s>The following supplementary material is available for this article:</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Challenges in the management of epilepsy in resource-poor countries</title>
		<author>
			<persName><forename type="first">K</forename><surname>Radhakrishnan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="323" to="330" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Antiepileptic drugs 2012: recent advances and trends</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Sirven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Noe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hoerth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drazkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mayo Clin Proc</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="879" to="889" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Management of epilepsy in adolescents and adults</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Brodie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>French</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="323" to="329" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs</title>
		<author>
			<persName><forename type="first">C</forename><surname>Piana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Antunes</forename><surname>Nde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Pasqua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Metab Toxicol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="341" to="358" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The clinical impact of pharmacogenetics on the treatment of epilepsy</title>
		<author>
			<persName><forename type="first">W</forename><surname>Loscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Klotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zimprich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1" to="23" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Berkovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="686" to="689" />
			<date type="published" when="1996">1996-2008. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications</title>
		<author>
			<persName><forename type="first">U</forename><surname>Klotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacokinet</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="271" to="279" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Defining the clinical role of pharmacogenetics in antiepileptic drug therapy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dlugos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Buono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Ferraro</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics J</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="357" to="359" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sporis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bozina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Basic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Coll Antropol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="41" to="45" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The potential of pharmacogenetics in the treatment of epilepsy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Depondt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Paediatr Neurol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="57" to="65" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Key factors in the discovery and development of new antiepileptic drugs</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bialer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>White</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Drug Discov</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="68" to="82" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The pharmacologic basis of antiepileptic drug action</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sankar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1471" to="1483" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin</title>
		<author>
			<persName><forename type="first">P</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Biton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Faure</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1189" to="1196" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lambeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nocka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="9861" to="9866" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Casillas-Espinosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Casarosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caleo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Psychiatry</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">19</biblScope>
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
	<note>Epilepsia</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">De novo STXBP1 mutations in mental retardation and nonsyndromic epilepsy</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Hamdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Piton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gauthier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="748" to="753" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Research Highlights: highlights from the latest articles focusing on a new gene set for better drug response prediction of epilepsy patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Baghel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jajodia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kukreti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="581" to="586" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Discovery of epilepsy susceptibility genes: implications for therapy development and pharmacogenomics</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Ferraro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="731" to="734" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs</title>
		<author>
			<persName><forename type="first">S</forename><surname>Grover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gourie-Devi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kukreti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet Genom</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="447" to="465" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Cocatotila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="389" to="399" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the commission on classification and terminology of the international league against epilepsy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Cocatotila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="489" to="501" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">A simple salting out procedure for extracting DNA from human nucleated cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Dykes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Polesky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1215</biblScope>
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="W600" to="W605" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Whole genome data analysis toolset</title>
		<author>
			<persName><forename type="first">Purcell</forename><forename type="middle">S</forename><surname>Plink</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Efficiency and power in genetic association studies</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>De Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yelensky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pe'er</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Daly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Altshuler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1217" to="1223" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A new statistical method for haplotype reconstruction from population data</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Donnelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="978" to="989" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Association mapping in structured populations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Donnelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="170" to="181" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The role of haplotypes in candidate gene studies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Clark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genet Epidemiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="321" to="333" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Yin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Neurosci Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="566" to="572" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drugresistant epilepsy in a north Indian population</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kumari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lakhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Garg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Indian J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S32" to="S40" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kumari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lakhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kalita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">K</forename><surname>Misra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mittal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Seizure</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="237" to="241" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Evidence for epistatic interactions in antiepileptic drug resistance</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="71" to="76" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Depondt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sisodiya</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="5507" to="5512" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet Genom</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="721" to="726" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zimprich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stogmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1108" to="1109" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">SCN1AIVS5-91G&gt;A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kumari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lakhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochimie</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1350" to="1353" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Association between SCN1A polymorphism and carbamazepine-resistant epilepsy</title>
		<author>
			<persName><forename type="first">T</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ishitsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="304" to="307" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy</title>
		<author>
			<persName><forename type="first">W</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsy Res</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="231" to="237" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Will tomorrow&apos;s medicines work for everyone?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Goldstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="S34" to="S42" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy</title>
		<author>
			<persName><forename type="first">I</forename><surname>Manna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gambardella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bianchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="e40" to="e44" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Poon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Ng</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet Genom</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="989" to="998" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Korean Med Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="62" to="68" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lakhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kumari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">K</forename><surname>Misra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kalita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pradhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mittal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="214" to="220" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Namazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Azarpira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Javidnia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Iran J Basic Med Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1215" to="1220" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Daci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Beretta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vllasaliu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0142408</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Zhong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1499" to="1512" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhong Nan Da Xue Xue Bao Yi Xue Ban</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="433" to="441" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">SCN1A variations and response to multiple antiepileptic drugs</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>O'doherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Dibbens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Suppiah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics J</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="385" to="389" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Gene-wide tagging study of the effects of common genetic polymorphisms in the a subunits of the GABA(A) receptor on epilepsy treatment response</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1849" to="1856" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures</title>
		<author>
			<persName><forename type="first">S</forename><surname>Balan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sathyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Radha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joseph</forename><forename type="middle">V</forename><surname>Radhakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Banerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet Genomics</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="605" to="610" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Haerian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mohamed</forename><forename type="middle">Z</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1153" to="1166" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Haerian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1477" to="1485" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Influence of the SCN1A IVS5N + 5 G&gt;A Polymorphism on Therapy with Carbamazepine for Epilepsy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Sterjev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kiteva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cvetkovska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Balkan J Med Genet</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="19" to="24" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="159" to="169" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>S Anchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Herranz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Seizure</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="93" to="101" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
